We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sorrento Therapeutics has entered into a merger agreement to acquire gene-encoded therapeutics firm SmartPharm for an aggregate of up to $19.4m shares of Sorrento common stock.